WILLOW BIOSCIENCES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.09 CAD | 0.00% |
|
0.00% | -10.00% |
| Apr. 01 | Willow Biosciences Narrows 2023 Loss YOY | MT |
| Mar. 29 | Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 50.49 | 113 | 55.6 | 14.23 | 12.42 |
| Enterprise Value (EV) 1 | 31.75 | 97.42 | 25.6 | -0.7782 | 10.8 |
| P/E ratio | -1.04 x | -2.83 x | -8.79 x | -0.96 x | -0.95 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 11,015 x | 11,300 x | 418 x | 17.3 x | 10.6 x |
| EV / Revenue | 6,927 x | 9,742 x | 192 x | -0.95 x | 9.21 x |
| EV / EBITDA | -2.79 x | -6.76 x | -1.24 x | 0.05 x | -0.86 x |
| EV / FCF | -3.29 x | -13.6 x | -2.23 x | 0.1 x | -1.73 x |
| FCF Yield | -30.4% | -7.35% | -44.9% | 1,010% | -57.7% |
| Price to Book | 2.29 x | -202 x | 1.87 x | 0.87 x | 3.62 x |
| Nbr of stocks (in thousands) | 78,892 | 96,584 | 123,545 | 123,720 | 124,242 |
| Reference price 2 | 0.6400 | 1.170 | 0.4500 | 0.1150 | 0.1000 |
| Announcement Date | 3/24/20 | 3/23/21 | 3/29/22 | 3/21/23 | 3/29/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0169 | 0.004584 | 0.01 | 0.133 | 0.821 | 1.172 |
| EBITDA 1 | -1.598 | -11.38 | -14.4 | -20.67 | -16.5 | -12.62 |
| EBIT 1 | -1.645 | -13.08 | -16.85 | -23.2 | -18.4 | -13.48 |
| Operating Margin | -9,723.67% | -285,269.28% | -168,460% | -17,440.6% | -2,241.17% | -1,149.91% |
| Earnings before Tax (EBT) 1 | -1.645 | -46.15 | -33.95 | -6.14 | -14.76 | -13.03 |
| Net income 1 | -1.645 | -44.57 | -33.95 | -6.14 | -14.81 | -13.03 |
| Net margin | -9,723.67% | -972,220.55% | -339,460% | -4,616.54% | -1,804.38% | -1,111.69% |
| EPS 2 | -0.7501 | -0.6184 | -0.4140 | -0.0512 | -0.1198 | -0.1049 |
| Free Cash Flow 1 | -1.2 | -9.651 | -7.165 | -11.49 | -7.857 | -6.234 |
| FCF margin | -7,094.29% | -210,531.26% | -71,647.5% | -8,640.13% | -957.03% | -531.9% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/8/19 | 3/24/20 | 3/23/21 | 3/29/22 | 3/21/23 | 3/29/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 0.44 | 18.7 | 15.6 | 30 | 15 | 1.63 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.2 | -9.65 | -7.16 | -11.5 | -7.86 | -6.23 |
| ROE (net income / shareholders' equity) | -303% | -390% | -317% | -42.2% | -64.3% | -132% |
| ROA (Net income/ Total Assets) | -126% | -46.9% | -37.8% | -51% | -43.3% | -67.9% |
| Assets 1 | 1.301 | 95.02 | 89.87 | 12.04 | 34.24 | 19.2 |
| Book Value Per Share 2 | 0.3600 | 0.2800 | -0.0100 | 0.2400 | 0.1300 | 0.0300 |
| Cash Flow per Share 2 | 0.1600 | 0.2500 | 0.1600 | 0.2400 | 0.0900 | 0.0300 |
| Capex 1 | 0.2 | 6.71 | 0.95 | 1.67 | 0.68 | 0.61 |
| Capex / Sales | 1,199.34% | 146,431.57% | 9,520% | 1,255.64% | 82.83% | 51.62% |
| Announcement Date | 5/8/19 | 3/24/20 | 3/23/21 | 3/29/22 | 3/21/23 | 3/29/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -10.00% | 8.36M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- WLLW Stock
- Financials Willow Biosciences Inc.
